Palisade bio enters into strategic collaboration with strand life sciences to advance precision medicine approach

– collaboration grants palisade bio access to cutting-edge expertise and tools in bioinformatics – partnership marks a significant value-driving milestone in palisade bio's mission to redefine uc treatment through targeted interventions based on pde4-related biomarkers carlsbad, ca, april 23, 2024 (globe newswire) -- palisade bio, inc.  (nasdaq: pali) (“palisade”, “palisade bio” or the “company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with strand life sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (uc) therapy. the collaboration with strand life sciences provides palisade bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to pde4 inhibitors.
PALI Ratings Summary
PALI Quant Ranking